Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 8/20 | 0.55 |
| ▸ | CA1 | P00915 | 10/20 | 0.53 |
| ▸ | CA2 | P00918 | 10/20 | 0.53 |
| ▸ | CA9 | Q16790 | 10/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.52 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.51 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4148374 | 0.86 | HDAC3 (0.64) | IKBKBCA1CA2CA9CA12 | |
| SCHEMBL3647596 | 0.82 | DKK1 (0.72) | IKBKBCA1CA2CA9CA12 | |
| SCHEMBL4147267 | 0.81 | KDM4E (0.52) | IKBKBCA1CA2CA9CA12 | |
| SCHEMBL24334956 | 0.76 | PTGS2 (0.54) | IKBKBMAPK8MAPK10PTGS2 | |
| SCHEMBL5091711 | 0.74 | MAPK8 (0.55) | IKBKBMAPK8MAPK10 | |
| SCHEMBL24334967 | 0.74 | PTGS2 (0.64) | IKBKBPTGS2 | |
| SCHEMBL7464625 | 0.74 | DYRK1A (0.52) | — | |
| SCHEMBL5089218 | 0.73 | IKBKB (0.57) | IKBKBMAPK8MAPK10 | |
| SCHEMBL7524252 | 0.72 | CDK1 (0.69) | IKBKB | |
| SCHEMBL3524644 | 0.72 | IKBKB (0.71) | IKBKBMAPK8MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048282-A1 | PYRIMIDINE SULFONAMIDE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WYETH (US) | 2009-02-19 | — | — | US | claimed |
| US-20090048282-A1 | PYRIMIDINE SULFONAMIDE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WYETH (US) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048282-A1 | PYRIMIDINE SULFONAMIDE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WNT1, CTNNB1, WNT3A | IKBKB 1593/4885CA1 4796/4885CA2 4551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.